WO1999051256A3 - Use of l-glu-l-trp in the treatment of hiv infection - Google Patents

Use of l-glu-l-trp in the treatment of hiv infection Download PDF

Info

Publication number
WO1999051256A3
WO1999051256A3 PCT/US1999/007297 US9907297W WO9951256A3 WO 1999051256 A3 WO1999051256 A3 WO 1999051256A3 US 9907297 W US9907297 W US 9907297W WO 9951256 A3 WO9951256 A3 WO 9951256A3
Authority
WO
WIPO (PCT)
Prior art keywords
trp
glu
treatment
hiv infection
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/007297
Other languages
French (fr)
Other versions
WO1999051256A2 (en
Inventor
Lawrence R Green
Nickolay V Sinackevich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CYTRAN Ltd
Original Assignee
CYTRAN Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CYTRAN Ltd filed Critical CYTRAN Ltd
Priority to AU34667/99A priority Critical patent/AU3466799A/en
Priority to CA002326760A priority patent/CA2326760A1/en
Priority to EP99916320A priority patent/EP1067951A2/en
Publication of WO1999051256A2 publication Critical patent/WO1999051256A2/en
Publication of WO1999051256A3 publication Critical patent/WO1999051256A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides methods for the treatment of HIV infection by administering effective amounts of L-Xaa-L-Trp, wherein Xaa is Glu, Ile or Leu, and derivatives and analogs thereof.
PCT/US1999/007297 1998-04-03 1999-04-02 Use of l-glu-l-trp in the treatment of hiv infection Ceased WO1999051256A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU34667/99A AU3466799A (en) 1998-04-03 1999-04-02 Use of l-glu-l-trp in the treatment of hiv infection
CA002326760A CA2326760A1 (en) 1998-04-03 1999-04-02 Use of l-glu-l-trp in the treatment of hiv infection
EP99916320A EP1067951A2 (en) 1998-04-03 1999-04-02 Use of l-glu-l-trp in the treatment of hiv infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5509298A 1998-04-03 1998-04-03
US09/055,092 1998-04-03

Publications (2)

Publication Number Publication Date
WO1999051256A2 WO1999051256A2 (en) 1999-10-14
WO1999051256A3 true WO1999051256A3 (en) 1999-12-09

Family

ID=21995541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/007297 Ceased WO1999051256A2 (en) 1998-04-03 1999-04-02 Use of l-glu-l-trp in the treatment of hiv infection

Country Status (4)

Country Link
EP (1) EP1067951A2 (en)
AU (1) AU3466799A (en)
CA (1) CA2326760A1 (en)
WO (1) WO1999051256A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001279313B2 (en) 2000-08-04 2007-03-01 Ampio Pharmaceuticals, Inc. Method of using diketopiperazines and composition containing them
CA3050734A1 (en) 2003-05-15 2004-12-02 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
US8507496B2 (en) 2010-09-07 2013-08-13 Dmi Acquisition Corp. Treatment of diseases
EA027343B1 (en) 2011-10-10 2017-07-31 Ампио Фармасьютикалз, Инк. Implantable medical devices with increased immune tolerance, and methods for making and implanting
EP2766029B1 (en) 2011-10-10 2020-03-25 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
CA2846394A1 (en) 2011-10-28 2013-05-02 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
BR112015020469A2 (en) 2013-03-15 2020-01-28 Ampio Pharmaceuticals Inc USES OF DA-DKP, COMPOSITION AND METHOD FOR THE SUPPLY OF STEM CELLS TO UMINDIVIDUAL
AU2015305611B2 (en) 2014-08-18 2020-04-23 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
US11027287B2 (en) * 2018-07-30 2021-06-08 Metso Minerals Industries, Inc. Gyratory crusher including a variable speed drive and control system

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0423077A1 (en) * 1989-10-05 1991-04-17 POLIFARMA S.p.A. Tripeptide compounds and their pharmaceutical use as immunomodulators
WO1994020063A2 (en) * 1993-03-04 1994-09-15 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
EP0423077A1 (en) * 1989-10-05 1991-04-17 POLIFARMA S.p.A. Tripeptide compounds and their pharmaceutical use as immunomodulators
WO1994020063A2 (en) * 1993-03-04 1994-09-15 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GILL PS ET AL: "Preliminary results of a randomized study of IM-862 nasal solution in the treatment of patients with AIDS-related Kaposi's sarcoma", BLOOD, vol. 90, no. 10, 15 November 1997 (1997-11-15), pages 135a, XP002118779 *

Also Published As

Publication number Publication date
CA2326760A1 (en) 1999-10-14
WO1999051256A2 (en) 1999-10-14
EP1067951A2 (en) 2001-01-17
AU3466799A (en) 1999-10-25

Similar Documents

Publication Publication Date Title
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
WO2003000200A3 (en) β-2'-OR 3'-HALONUCLEOSIDES
TW371628B (en) Composition for treating condyloma acuminata
AU635358B2 (en) Transdermal administration of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole
SE9504077D0 (en) Liquid absorbent article considered for single use
IE891798L (en) Novel ó-glucosidase inhibitors
EP1273298A3 (en) Ritonavir in combination with an additional HIV protease inhibitor for treating aids
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
AU1067599A (en) Peptide compositions for the treatment and prevention of hiv infection
AU2636602A (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
EE03514B1 (en) A combination of compounds for the treatment of HIV infection or AIDS, its use and a pharmaceutical composition
EP0373771A3 (en) New pharmaceutical uses for cystatins
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
MY124071A (en) Treatment of viral disease in swine
EP0385909A3 (en) A kit or composition for the prevention or treatment of HIV-1 infections
WO1998044913A3 (en) Compositions containing mkc-442 in combination with other antiviral agents
MD980129A (en) Antiherpetic remedy
AU6877587A (en) Expellants of phytopathogenic microbes
AU1031497A (en) Dithiazoldioxides and the use thereof as microbicides
WO2000002579A3 (en) Component b as angiogenic agent in combination with human growth factors
EP0369810A3 (en) Paf antagonists as anti-hyperendothelinemia agents
CA2014884A1 (en) 5,11-dihydro-6h-pyrido[2,3-b][1,4]benzodiazepin-6-ones and -thiones and their use in the prevention or treatment of aids
WO2000045851A3 (en) Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2326760

Country of ref document: CA

Ref country code: CA

Ref document number: 2326760

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 34667/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999916320

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999916320

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999916320

Country of ref document: EP